QuidelOrtho 的收益超出预期，但由于商誉费用、较低的指导以及 FDA 的新测试批准，股价在 2025 年 11 月 6 日下跌了 12.8%。 QuidelOrtho beat earnings estimates but saw stock drop 12.8% on Nov. 6, 2025, due to a goodwill charge, lower guidance, and a new FDA test approval.

Quidel Ortho(QDEL)报告说,第三季度收入为每股0.80美元,比上一年的7.271亿美元增加0.299亿美元,但比上一年减少3.7%。 QuidelOrtho (QDEL) reported third-quarter earnings of $0.80 per share, beating estimates by $0.29, and revenue of $699.9 million, up from last year’s $727.1 million, though down 3.7% year-over-year. 尽管收入节减,2025年11月6日股票下跌了12.8%,原因是大量非现金商誉减值收费造成公认会计原则净损失,以及全年调整的EPS指南减少10.6%。 Despite the earnings beat, the stock dropped 12.8% on November 6, 2025, due to a large non-cash goodwill impairment charge that caused a GAAP net loss, and a 10.6% reduction in full-year adjusted EPS guidance. 该公司还获得了FDA对新诊断测试的批准. The company also received FDA approval for a new diagnostic test. 到目前为止,股票存量下降了47.9%,从52周的最高水平下降50.7%。 The stock is down 47.9% year-to-date and 50.7% from its 52-week high.